Trial Profile
CONKO-006 additive therapy in the R1 resected pancreatic cancer with Gemcitabine plus sorafenib versus Gemcitabine plus placebo over 12 months - one double-blind, placebo-controlled Phase IIb study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 29 Apr 2021 Results of pooled analysis from three clinical studies: CONKO-001, CONKO-005, and CONKO-006 published in the European Journal of Cancer
- 08 Sep 2017 Status changed from active, no longer recruiting to completed.
- 11 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by German Clinical Trials Register record.